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Anette Schrag 19, Antonio P. Strafella20, Beth Vernaleo21, Daniel Weintraub22,23 and Zoltan Mari24
Anxiety is a severe problem for at least one-third of people living with Parkinson’s disease (PD). Anxiety appears to have a greater
adverse impact on quality of life than motor impairment. Despite its high prevalence and impact on daily life, anxiety is often
undiagnosed and untreated. To better address anxiety in PD, future research must improve knowledge about the mechanism of
anxiety in PD and address the lack of empirical evidence from clinical trials. In response to these challenges, the Parkinson’s
Foundation sponsored an expert meeting on anxiety on June 13th and 14th 2018. This paper summarizes the findings from that
meeting informed by a review of the existing literature and discussions among patients, caregivers, and an international, clinician-
scientist, expert panel working group. The goal is to provide recommendations to improve our understanding and treatment of
anxiety in PD.
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INTRODUCTION
Anxiety occurs in at least one-third of all people with Parkinson’s
disease (PWP) and is one of the main determinants of quality of
life.1,2 In 2016, at the World Parkinson Congress in Portland,
Oregon, the Parkinson’s Foundation surveyed Congress attendees
with Parkinson’s disease (PD) and their care partners regarding
their unmet needs. The survey was part of the Foundation’s
Community Choice Research Award initiative, which aims to
identify unmet needs within the PD community and address those
needs through targeted workshops and research funding.
Respondents were given 33 choices and were asked to rank their
top 3 unmet needs. Of the 1026 responses received, 141 (13.7%)
ranked anxiety as their top unmet need, and 434 (42.3%) ranked
anxiety as one of their top three unmet needs. The prominence of
anxiety as an unmet need echoes findings from the Parkinson’s UK
earlier priority-setting exercise. Using an iterative modified
nominal group technique, 1000 individuals, including those with
PD, caregivers, family and friends, and healthcare and social
service professionals, developed a list of unmet research areas. A
subsequent stakeholder consensus meeting identified the top 10
management research priorities; stress and anxiety ranked second
after balance and falls.3
As a result of the 2016 survey, the Parkinson’s Foundation
organized a workshop focused on anxiety in PD in order to discuss
gaps in knowledge for both research and care and propose plans
for moving the field forward. The June, 2018 workshop
participants comprised 16 scientists and clinicians with expertise
in PD, including movement disorder neurologists, psychiatrists,
psychologists, and PD researchers. This provided an opportunity
for specialists from different disciplines to learn how each
approached the clinical problem. To provide perspective from
the patient side, six members of the PD community attended.
These included a family of three (father with Parkinson’s, mother
care partner, and adult son) two patients, and a spouse. When
asked to share their experience, the family said:
“I was diagnosed with Parkinson’s 15 years
ago when I was 43 years old. Before my
diagnosis, I was a very active husband,
father, son, trial lawyer, and musician. I was
easygoing and not anxious about anything!
Anxiety makes me feel indecisive and
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worsens my PD symptoms, particularly
slowness and rigidity, tremor, dyskinesia, and
body temperature. Anxiety produces
unwarranted fear of simple things in life
such as how to walk through a room, enter
an elevator, airplane or train, choose a meal
from the refrigerator, or select my clothing…
I think it is essential for the PD community to
consider anxiety and emotional needs at the
same level as the motor functions since they
are so intertwined and not addressing one
can interfere with other interventions that
might work otherwise.”
- Len Schwartz, person with Parkinson’s
“Anxiety has pervaded every aspect of our
lives, even more so than the physical
manifestations of PD. It has limited our
ability to interact with family and friends,
entertain, shop, travel, visit public spaces
and try new things. While the physical
symptoms can be bad enough on their own,
anxiety exacerbates them exponentially.”
-Sharon Aldouby, wife and care partner
“As a son of someone with Parkinson’s, I've
always tried to understand the mental toll on
my father from this disease. Knowing the
difference between what's being caused by
the PD and my dad’s actual mindset is
essential for me to understand his needs and
help him stay grounded.”
-Matt Schwartz, adult son of a person with Parkinson’s
Another attendee wrote:
“Anxiety turns my mind to jello. It causes me to
think in unproductive ways. It destroys my
sense of self -worth and renders me almost
incapable of making simple choices.”
-Person with Parkinson’s
Anxiety can dramatically impact many aspects of a person’s life
and needs to be addressed in order to improve quality of life for
PWP, their family members, and care partners. This review
describes the current state of knowledge on anxiety in PD with
regard to its presentation and risk factors, clinical approaches to
measurement of anxiety, available pharmacological and non-
pharmacological therapies, approaches for effective multidisci-
plinary care, and strategies that help caregivers cope with the
increased burden of anxiety in their loved ones.
Anxiety can be assessed as a clinical symptom or a clinical
syndrome, with advantages and limitations to each approach.
Typically, symptoms can be identified quickly using standardized
scales, and specialized training is not required. By contrast,
diagnosis of a syndrome, a collection of signs and symptoms that
occur together and are usually thought to have a central or shared
cause, is more time consuming and requires the synthesis of
information, usually requiring specialized training. To that end,
syndromes are more reliably associated with an underlying
mechanism as compared to symptoms. For example, cough, as a
symptom, might be explained by a number of causes, e.g.,
allergies, the common cold, or tuberculosis, whereas the
syndrome of a cough accompanied by bloody sputum, weight
loss, fatigue, fever, chills, and chest pain, offers important clues
about etiology. Similarly, assessing anxiety in PD as a syndrome is
more likely to advance knowledge of underlying mechanisms.
A systematic review of 45 articles published up to September
2015 describing anxiety in a total of 2399 patients found that the
point prevalence of anxiety disorders in PD is 31%.1 The studies
were conducted in countries in Asia, Australia, Europe, North and
South America and most—39 of 45—were conducted in out-
patient and community settings making this a reasonable
estimate of the global prevalence of anxiety in PD. The review
found that the most common diagnoses were generalized anxiety
disorder (GAD) 14.1%, social phobia 13.8%, and anxiety disorder not
otherwise specified (NOS) 13.3%. As a third of patients (31.1%) met
criteria for two or more anxiety disorders, the authors raised
questions about the construct validity of the Diagnostic and
Statistical Manual (DSM) anxiety classifications when applied to
PWP. The incidence of anxiety disorders in PD is not known. Studies
attempting to determine incidence will first have to address the
question of when PD starts, as numerous studies show that anxiety
is often present before motor symptoms are detected.4–6 Genes
associated with PD, a yet to be identified biomarker, or prodromal
conditions such as idiopathic RBD may be useful in determining
when the association between PD and anxiety begins.
The point prevalence of anxiety disorders in PD is generally
thought to be higher than in non-PD populations. Reports on
anxiety rates across different populations are problematic because
anxiety is frequently reported as a symptom, versus at the level of
a syndrome, and studies rarely control for overall disability level. In
the few studies with direct comparisons of anxiety rates, findings
often differ by anxiety disorder type.7–9 For example, in one of the
first studies on this issue, Stein MB et al. found greater prevalence
of panic disorder and social phobia in PD as compared to multiple
sclerosis, type I diabetes, and rheumatoid arthritis, after controlling
for disease-related disability.8 In a comparison of lifetime
prevalence of anxiety in PD to that in dystonia patients and
healthy controls from the Epidemiologic Catchment Area study,
Lauterbach et al.9 found, after controlling for age, gender, and
race, higher rates of GAD and social phobia in dystonia compared
to PD, and higher rates of simple phobia in PD than in dystonia.
Knowledge of the relative prevalence of anxiety syndromes in PD
and other neurodegenerative and neurological diseases may
provide clarity regarding shared or unique phenomena and focus
investigations of underlying mechanisms and treatment.
In PD, occurrence of clinical anxiety syndromes that are unique
to PD may also point to unique underlying mechanisms. Several
studies have captured these potentially ‘PD-specific’ anxiety
disorders using the DSM diagnostic category ‘Anxiety disorder
NOS’.10–13 Common presentations of ‘NOS’-type anxiety include: a
‘panic-like’ disorder that does not meet DSM criteria for avoidance
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behavior between episodes, episodic anxiety associated with
wearing off of dopaminergic medications, and an anticipatory
anxiety in which the individual becomes distressed in advance of
and often avoids events in the future. Anxiety in PD can often
involve symptoms related to thermoregulation, hypotension,
hyperventilation, and trembling, which may represent phenom-
enological overlap with autonomic dysfunction and other PD-
related somatic symptoms.10 Research on these apparent ‘PD-
specific’ anxiety syndromes is needed to determine the signifi-
cance of their unusual presentations and to facilitate their
diagnosis and clinical management. An alternative explanation
or conceptualization of ‘PD-specific’ anxiety is that while the
circuity involved in the production of anxiety is universal, the way
PD pathology compromises the circuit may be different than the
way ‘idiopathic’ anxiety disorders are generated or may alter the
clinical expression of symptoms.
The more recent PROMS-PD study14 overcame the limitations of
many previous studies, which were based on a single assessment
of anxiety in relatively small, convenience samples of PWP. This
prospective, multicenter, longitudinal study assessed a cohort of
513 PWP annually for up to 4 years. A data-driven analysis
identified four reliable classes to which each person could be
assigned. At each time point 54–59% of the participants fell into a
class labeled ‘Psychologically Healthy’ with a very low probability
of any significant anxiety or depression related symptom. The
remaining three classes were all associated with significant
psychological distress, characterized by varying probabilities of
significant anxiety-related symptoms, with or without co-occurring
depressive symptoms. Within the distress classes, the anxiety-
related profiles revealed were dominated by tension and rest-
lessness, worry, generalized anxiety/panic, irritability, fatigue, slow
thinking and poor concentration. Although formal diagnoses were
not assigned, such a profile is most consistent with GAD.
The PROMS-PD study also provided the ability to track the
pattern of stability or transition of individuals between classes.
Overall, 51% were classified as ‘remaining healthy’ throughout the
study, with only 8.6% of those in the ‘healthy’ class at baseline
transitioning into a ‘distress class’ subsequently. Conversely, the
majority of those in one of the three distress-related classes
remained in one of those classes between assessments, with 34%
‘remaining distressed’ throughout, and only 6.5% transitioning
from a distress group into the Psychologically Healthy group,
despite many reporting receiving treatment for their anxiety/
depression.
This study reveals a number of important findings. First, while
depressive symptomatology was relatively common in the cohort,
the anxiety-related symptoms were far more common. Second,
the data-driven approach failed to identify a class of patients with
prominent depressive symptomatology without co-occurring
anxiety symptoms, while the opposite pattern was observed.
Third, over time patients transitioned between the mixed
depression and anxiety symptoms profile and anxiety dominant
profile. Fourth, psychological distress (anxiety +/− depressive
symptoms) remained chronic, despite the fact that many
individuals were receiving treatment. Finally, even in the most
severe group, 40–60% reported receiving no treatment of their
anxiety or depression at any time point.
Only a few studies have specifically explored the risk factors for
anxiety in PD identifying both PD-specific and non-specific factors.
PD-specific risk factors for anxiety include younger age at
onset14,15 motor fluctuations,14–16 shorter disease duration16 faster
rate of progression14 greater disease severity14,15 postural
instability gait disorder subtype15,17 dysautonomic features18
REM sleep behavior disorder18 and larger echogenic areas in the
substantia nigra18 GAD and mixed anxiety in PD have been linked
to younger age.14,16
Non-specific risk factors include female gender,4,16,18,19 history
of anxiety16 and depression12,13,18 and family history of psychiatric
disorders.12,13 Psychological risk factors have also been implicated.
Reliance on emotion-focused, as opposed to problem-focused
coping skills, perception of loss of internal and external control
over disease symptoms, less social support and avoidant
personality traits, have been associated with increased symptoms
of anxiety.20
The association between anxiety and motor fluctuations, the
significant exacerbation of anxiety provoked by dopamine with-
drawal, suggests that neurodegeneration of the dopaminergic
pathways is involved in anxiety in PD. This is also supported by a
recent study showing that in newly-diagnosed, drug naïve
patients, lower DA uptake at the caudate was associated with
more severe trait anxiety.21 However, increasing L-dopa has not
been shown to reliably reduce anxiety in treated PWP. The
pathophysiology of PD-related anxiety disorders is complex and
remains to be elucidated. In rats, the unilateral 6-
hydroxydopamine (6-OHDA) lesion of the medial forebrain bundle
induces decreased dopamine levels in the limbic regions (striatum,
medial prefrontal cortex, amygdala, and hippocampus) and causes
anxiety-like behaviors.22 It also disrupts the serotoninergic
modulation of the neurons of the amygdala.22–24 This imbalance
between DA and 5HT activity might be an etiological and
pathophysiological factor for anxiety in PD.24 This was also
suggested by studies in monkeys25 and in early-diagnosed drug-
naïve PD patients.26 In PD, hypofunction of the amygdala might
play a key role in the development of anxiety disorders.27 The
basolateral amygdala is a densely connected “hub” relaying
sensory information to the central amygdala which is the major
efferent pathway with outputs namely to the frontal cortex
(representation of fear attributes) and the hippocampus (memory
of fear). However, although the role of the amygdala in anxiety
and fear has been well studied in the general population, there is
still controversy and we are unsure how it can be applied to PD.
For instance, it is debated whether the amygdala is centrally
responsible for both the autonomic/behavioral reaction to anxiety
and the cognitive-emotional experience (‘central fear generator’
hypothesis) or part of a ‘two-system’ framework that requires
additional circuitry for the autonomic/behavioral response. (as
reviewed in Fanselow MS and Pennington ZT 2018).
So far, only twelve studies have been published. Most were PET
or SPECT studies and only three were volumetric studies.21,28–38
Overall, the functional studies of anxiety in PD showed involve-
ment of the striatum and of the DA and 5HT pathways. The
anatomical studies showed reductions in the volume of several
brain areas, namely the amygdala, the anterior cingulate cortex
and the orbito-frontal cortex. Recent connectivity studies showed
that anxiety in PD was related to changes in the striatum-frontal
cortex network.39,40 Hence, key structures in the processing of
emotions in general and in the neurocircuitry of fear, in particular,
seem to be involved.41 However, all these studies, except one,37
were correlation studies in PWP without established anxiety
disorders, meaning the changes might be due to factors other
than the presence or absence of anxiety. Moreover, anxiety
measures were not always optimal, namely many used anxiety
scales for which there is a high overlap between symptoms of
anxiety and those of PD. Further studies directly comparing PWP
with and without anxiety are thus needed. Moreover, as all these
regions are part of a large network, additional studies using
innovative structural and functional connectivity approaches are
required.
Given the high prevalence and adverse impact of anxiety
syndromes in PWP the use of an anxiety rating scale may be
helpful for screening, determining the severity of symptoms, and
to quantify effects of treatment.
Whereas depression rating scales have been validated and used
for decades in PD,42 a Movement Disorder Society (MDS) task
force concluded in 2008 that none of the available anxiety rating
scales were validated for use in PD.43 The first validation study of
G.M. Pontone et al.
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the Beck Anxiety Inventory (BAI), the Hamilton Anxiety Rating
Scale (HAMA), and the Hospital Anxiety and Depression Scale
(HADS) was done by an international consortium in 2011. This
consortium reported that while some clinimetric properties of
these scales are acceptable, such as ease of completion (e.g.,
acceptability), known groups validity, inter-rater reliability and
test-retest reliability, there are also important shortcomings such
as the limited construct validity, the low convergent validity with
other anxiety rating scales, as well as low divergent validity with
depression rating scales. The latter implies that these scales
cannot separate depression from anxiety.44 None of the existing
scales assessed avoidance behavior, and they generally lacked
sensitivity in the lower score ranges (i.e., floor effect), leading to
under recognition of anxiety. Another study validated the Geriatric
Anxiety Inventory (GAI) in PWP, with assessment of a limited
number of clinimetric properties. The GAI showed good internal
consistency and test-retest reliability.45
The development and validation of the Parkinson Anxiety Scale
(PAS) by the same international consortium was intended to
overcome the clinimetric shortcomings of the existing anxiety
rating scales in PD.46 This consortium followed a strictly systematic
approach to the development of the scale. The general format of
the scale was formulated using the Delphi procedure. Sections of
the scale were defined based on clinical presentations of anxiety
using latent class analysis. Item selection was based on cannonical
correlation analysis performed using existing rating scales and the
database of the earlier validation study.47,48 The PAS is divided
into three sections that assess episodic anxiety, persistent anxiety,
and avoidance behavior. Clinimetric properties are superior to
those of other anxiety rating scales, with satisfactory acceptability,
distribution across score range, internal consistency, test-retest
reliability, inter-rater reliability, sensitivity, and specificity. The scale
has been translated in many languages.
However, there is still room for improvement. Those anxiety
rating scales that have been validated have all been studied in
PWP without dementia. Validation of these scales in PWP with
dementia remains to be done.49 Moreover, anxiety scales
specifically developed for patients with dementia in the general
population still need to be validated in the context of PD
dementia, such as the rating anxiety in dementia (RAID) scale. A
shortcoming of the PAS, as well as other anxiety scales, is that they
assess only common presentations of anxiety. Some presentations
of anxiety that are unique to PD are not assessed, such as anxiety
during ‘wearing-off’ of medication, anxiety during ‘off’ periods,
and situational anxiety e.g. during the performance of activities of
daily living that present a risk of falling.49,50 For this reason the
development of a PD-specific anxiety questionnaire has been
proposed. A preliminary study profiled 30 triggers of PD-related
anxiety. The presence of distress, worry, fear, agitation, embarrass-
ment, and avoidance were frequently reported as resulting from
motor symptoms including complications of medication for PD.11
This study will be the basis for the development of a new
inventory to assess PD specific triggers of anxiety, and resulting
behavior, in both research settings and clinical practice, named
the PD Specific Anxiety Inventory (PDSAI).
PWP are particularly vulnerable to side effects of some of the
most commonly-used pharmacological treatments of anxiety,
such as increased risk of falls and cognitive impairment in the case
of benzodiazepines or antihistamines.51 Therefore, there is a need
for non-pharmacological approaches, including behavioral inter-
ventions and neurostimulation. PWP have a high level of
willingness to participate in behavioral interventions for their
illness.52 The ideal behavioral intervention for PD would have the
following attributes: (1) it would be effective in reducing anxiety as
well as depression, given their frequent co-occurrence; (2) it would
improve or even prevent the decline in cognitive function
associated with PD; (3) it would be accessible in the community.
Physical exercise has few adequately powered trials to guide its
use for anxiety in PD but is of interest because of its overall benefit
to the motor symptoms of the disease. A recent RCT of 138 PWP
compared a mindfulness yoga program to a stretching and
resistance training exercise and found that the mindfulness yoga
program produced a comparable improvement in motor symp-
toms with the additional benefit of reducing anxiety and
depression.53 This suggests that ‘mind-body’ exercises may be
one of the most promising ways to meet the ideals stated above.
Psychotherapy and psychosocial interventions are known to be
effective for anxiety in general but only few studies have assessed
their effectiveness in PD.54
Cognitive behavioral therapy (CBT) is considered the gold
standard of psychotherapy treatments for anxiety. In PD anxiety,
only a few single-case or open label studies have been reported.
Overall, studies were limited by methodological weaknesses. They
were underpowered, enrolled patients with mixed depression and
anxiety symptoms and had variable results. Some studies showed
a significant reduction of depression and anxiety symptoms in the
CBT group compared with controls55 while others reported a
benefit on depression but no effect on anxiety.56 Moreover, long
term effects were also variable. More powerful, randomized,
controlled trials focused on the effects of CBT on anxiety are thus
needed. Some are in progress and their results will probably
provide guidelines on the best way to administer such therapy in
PWP with anxiety disorders.57
Mindfulness training has the potential for managing a variety of
neuropsychiatric conditions, including anxiety disorders. While the
concept of mindfulness is thousands of years old, protocol driven
mindfulness training courses have increased its presence in
Western medicine. Exemplary of this approach is mindfulness-
based stress reduction, or MBSR, a group-based 8-week introduc-
tion to mindfulness meditation that was created at University of
Massachusetts in the 1980s and is available throughout the US
and worldwide. MBSR is not specific to PD, but may be helpful for
both anxiety and cognitive functioning in older adults.58 No
published studies have demonstrated the effectiveness of mind-
fulness training in PD, although several pilot studies are ongoing
and preliminary findings are supportive.59–61 Another advantage
of mindfulness training is the potential to deliver it remotely, via
mHealth/telehealth, which may be more accessible to PD
populations with limited mobility.62 At this time, the evidence
for mindfulness training in PD is inconclusive;63 more research is
needed to test its effectiveness and innovative ways to deliver it
into the community.
Another approach that deserves study is to specifically target
some of the cognitive biases (e.g., biased attention to stimuli
signaling threat, or biases towards negative interpretations of
ambiguous situations). Cognitive bias modification interventions
are showing promise in the management of a range of anxiety
disorders including generalized anxiety,64 but have yet to be
systematically explored in PD. Such computer-based interventions,
if effective, have the potential to be simple, accessible and
economical ways to deliver interventions to people in their
own homes.
Non-invasive brain stimulation (NIBS) such as repetitive
transcranial magnetic stimulation (rTMS), and transcranial direct
current stimulation (tDCS) in the treatment of anxiety is still in its
infancy. rTMS is a non-invasive procedure in which cerebral
electrical activity is modulated by a rapidly changing magnetic
field. Outside the context of PD, there is some growing evidence
that GAD and panic disorders might benefit from rTMS,65 and that
anxiety can be reduced in patients with major depressive
disorders.66 In PD, few studies addressed the effect of NIBS on
anxiety. None of them had anxiety as a primary outcome. One
open label study in PD patients with treatment-resistant depres-
sion found a significant improvement on both depression and
anxiety following multiple sessions of 10 Hz rTMS over the right
dorsolateral prefrontal cortex (DLPFC) up to 6 weeks after
G.M. Pontone et al.
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treatment.67 Traditional tDCS delivers a constant low direct
current through an anodal and a cathodal electrode on the head.
In a study evaluating the impact of anodal tDCS over the left vs.
the right DLPFC on executive function in PD, a significant post-
treatment effect of left DLPFC stimulation vs. right and sham tDCS
stimulation was found in PD patients for depression but not for
anxiety.68 Apart from the fact that it is well tolerated, little
inference based on the current evidence can be made regarding
the use of NIBS as treatment for anxiety in PD. Additional large-
scale, randomized studies are warranted in PWP with moderate to
severe anxiety to determine the optimal protocols with respect to
stimulation parameters, timing and number of sessions.
Deep brain stimulation (DBS) is a neurosurgical procedure
which sends electrical impulses, through implanted electrodes, to
specific targets in the brain such as the subthalamic nucleus (STN)
and the internal global pallidus (GPi) for motor symptoms. Several
studies have investigated its effect on anxiety, more so for STN
stimulation than GPi. While results are heterogenous, at the group
level improvement of anxiety is apparent after DBS and more
pronounced in the short-term.69 However, some patients experi-
ence transient, clinically significant neuropsychiatric symptoms
including anxiety following DBS. These have been noted on
occasion after the reduction of dopamine therapy following STN
DBS with improvement after increasing it.70 A recent study
indicates that the exact placement of the electrode in the STN
may impact the various non-motor symptoms differently,
suggesting it may be possible to personalize DBS therapy by
tailoring it to the specific motor and non-motor symptom profile
including anxiety.71
There is thus a real need for additional studies on such
interventions targeting PD-related anxiety.
In contrast to treatment for depression, to date there is little trial
evidence for the pharmacological treatment of anxiety. Whilst off-
periods symptoms often include severe anxiety which improves
with dopaminergic medication,72,73 and anxiety is frequently part
of the dopamine agonist withdrawal syndrome, there have been
no randomized, placebo-controlled, clinical trials of medication for
the treatment of anxiety in PD. Clinicians most commonly
prescribe selective serotonin reuptake inhibitors (SSRIs) and
benzodiazepines. However, in the multicenter Study of Antide-
pressants in Parkinson’s Disease (SAD-PD) trial both paroxetine (an
SSRI) and venlafaxine XR (a serotonin norepinephrine reuptake
inhibitor or SNRI) were more effective than placebo for the
treatment of depressive symptoms, but neither demonstrated any
effect on a secondary anxiety measure.74 In fact, higher baseline
anxiety levels predicted poorer response to treatment of
depressive symptoms.75 A trial comparing desipramine and
citalopram with placebo for depression also did not show a
greater improvement of anxiety scores on these treatments than
on placebo. Another randomized placebo-controlled trial compar-
ing nortriptyline and paroxetine for the treatment of depression in
PD demonstrated no effect for paroxetine on a secondary anxiety
measure.76 In a trial of atomoxetine for the treatment of
depression, there was a non-significant suggestion for greater
improvement of anxiety as a secondary outcome measure
compared to placebo.77 However, none of these studies was
designed to detect changes in anxiety, so they highlight the need
to further evaluate treatment approaches for anxiety in PD.
Benzodiazepine therapy is not ideal given a side effect profile
including sedation, cognitive impairment or delirium, and balance
impairment associated with an increased risk of falls. Long term
use may also be associated with tolerance and increased risk of
dementia.78
There is currently a placebo-controlled, double-blind, pilot study
of buspirone in 27 participants with PD and anxiety underway to
test the tolerability of buspirone, a 5HT1A receptor partial agonist
with weak dopamine D2 and 5HT2 receptor activity,79 which has
been shown to be effective for the treatment of GAD.80–82 It has
been shown to be beneficial in PD in two small trials, but through
its effects on the dopaminergic system and weak affinity for D2
receptors could potentially be associated with worsening of PD
motor function. In addition, a large, placebo-controlled trial of the
antidepressants escitalopram and nortriptyline (Adept-PD) will
assess the impact of these medications on depression and anxiety
in patients with depression in PD in the UK.
Integrated care, also known as inter-disciplinary or multi-
disciplinary (“multi-D”) care, coordinated care, comprehensive
care, seamless care, or transmural care, is being adopted world-
wide in a variety of specialties and health care areas. There is an
ongoing process with reforms and new organizational arrange-
ments focusing on more coordinated and integrated forms of care
provision. Integrated care may be seen as a response to the
fragmented delivery of health and social services being an
acknowledged problem in many health systems.83–85 Integrated
care represents the highest level in the continuum of autonomy to
cooperation to integration.86
Integrated health care models have been found to be
efficacious compared to non-integrated delivery in decreasing
depression and anxiety scores in the elderly in general87 and there
is evidence for the benefit of multidisciplinary care for neurop-
sychiatric symptoms specifically in PD.88 Further, mindfulness-
based stress reduction showed positive patient-centered out-
comes and favorable health care utilization in an integrated health
care delivery system.89
The implementation of integrated or multidisciplinary care in
anxiety requires the reorganization of the current fragmented care
delivery setup, which is based on autonomy. It is necessary to
develop clinical pathways and instruction materials. Effective flow
of information and active multi-directional coordination is usually
achieved in the form of regular multidisciplinary meetings and
continuous electronic and optional occasional phone/personal
communications. Education and outreach are often a part of
integrated health care models. It is necessary to adopt formal
quality control metrics, which can be part of the meetings or
dedicated “circles” specifically for this purpose as part of the
implementation process. Implementation is often impeded due to
the current reimbursement systems and training curricula for
health care professionals.90,91 Despite these challenges, there is
evidence for the benefits of integrated care in mental health,86
specifically in neuropsychiatric symptoms (such as anxiety) in
PD,88 and supported by anxiety patients’ preference for integrated
care.92
Caregivers play an integral part in meeting the physical,
emotional, and financial needs of PWP and are critical members
of the healthcare team. Caregiving in PD is predominantly
provided by informal caregivers, mostly spouses. Estimates
suggest that caregivers assist PWP an average of 11 times
per day in early PD and up to 30 times per day in later stages of
the disease.93 Unfortunately, the majority of PD caregivers
experience burden in the context of their helping role, which
may be higher than that endured by caregivers in other medical
populations.94 Non-motor symptoms in PWP, such as anxiety,
have consistently been found to be one of the strongest
predictors of PD caregiver stress.95
Caregiver burden may increase the risk that caregivers will
engage in negative social exchanges with PWP, exacerbating the
PWPs’ symptoms of both PD and anxiety. Moreover, caregiver
burden is significantly associated with the caregivers’ poorer
recognition and understanding of both anxiety and depression in
PWP,96 negatively influencing the patient-caregiver dyadic rela-
tionship. Conversely, positive social support has been associated
with improved coping, as well as decreased disability, depression,
and anxiety in the PD population, even when controlling for
disease severity.97 Importantly, structured caregiver involvement
in CBT interventions for depression in PD, was the strongest
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predictor of patient treatment response, accounting for more than
25% of the variance in improvement trajectories.98
Improving anxiety in PD, and the integral relationship with the
caregiver can potentially be addressed in following ways: (i)
patient interventions to address non-motor symptoms and
increase independence in PWP, (ii) caregiver specific interventions
to treat caregiver psychological symptoms (i.e., referral for
individual counselling), and (iii) patient-caregiver dyadic interven-
tions. Given the reciprocal relationship between patient and
caregiver health, unique clinical considerations for caregiver
involvement in the treatment of anxiety in PD must be critically
evaluated on a case-by-case basis to best meet the needs of each
dyad. Factors such as the nature of the relationship between the
PWP and carepartner (spouse, child), quality and characteristics of
the relationship (active benefit-finding in the caregiver role vs.
anger and burden), and specific type of caregiver intervention
which may be most appropriate require careful consideration.
Dyadic intervention can be delivered in the form of marital/ family
interventions,99 parallel interventions,100 or partner-assisted inter-
ventions.101 For example, in a stable marital relationship
characterized by the reciprocal exchange of support, a partner
assisted intervention for anxiety in PD could be quite beneficial. A
partner assisted CBT intervention for anxiety in PD was success-
fully completed in a recent study.101 In this intervention, education
about anxiety in PD was delivered to both PD and their
carepartners, and the carepartner was included to informally
coach the PWP as they practiced the newly acquired CBT coping
skills learned throughout treatment (e.g., relaxation, meditation,
“talking back” to negative thoughts, exercise) in the home
environment. Caregivers were also asked to assist in the PWP
proactive engagement in their own lives and self-care, rather than
giving in to the withdrawal and avoidance behavior that
commonly characterizes anxiety in PD. The CBT intervention was
associated with significantly reduced anxiety immediately post-
intervention, with sustained reductions in anxiety at 6-month
follow-up, as well as significantly decreased caregiver burden at
post intervention.
Compared with depression, anxiety in PD has received less
overall attention to date (in part due to its significant overlap with
depression), although that has changed in recent years. Cross-
sectional studies have documented that up to 40% of PWP
experience anxiety symptoms or disorders, including GAD, panic
attacks, and agoraphobia or social phobia.12,15,102,103 Increasing
anxiety and discrete anxiety attacks have been associated with
non-motor fluctuations in patients with more advanced PD and
chronic exposure to higher-dose levodopa treatment, maybe
more so at the onset of “off” periods.12,15 However, anxiety in PD is
not simply a late disease manifestation, as there is an increased
frequency of anxiety disorders up to 20 years prior to PD diagnosis
on the basis of motor symptoms,4,104 providing biological
plausibility.
Advances have been made in the assessment of anxiety with the
recent development and validation of a PD-specific anxiety rating
scale (the PAS).46 A recently developed neuropsychiatric fluctua-
tions scale includes a number of anxiety items,105 and the new
movement disorders society-non-motor rating scale (MDS-NMS),
which is currently being validated, includes four anxiety questions
and a separate non-motor fluctuations section with an anxiety item.
Overall, relatively little is known about the etiology or
neurobiology of anxiety in PD. There have also been scant
pharmacological treatment studies for anxiety in PD and the
recent International Parkinson and MDS evidence-based review
for the treatment of non-motor symptoms of PD found that there
were no randomized clinical trials (RCTs) for the treatment of
anxiety disorders that met inclusion criteria.106 Antidepressant
treatment studies, in general, have not reported secondary benefit
for anxiety symptoms. For patients who experience anxiety as part
of an “off” state, PD medication adjustments can be made in an
attempt to decrease the duration and severity of these episodes.
However, some patients require treatment with benzodiazepines,
although this medication class must be used cautiously in PWP
due to their propensity to increase sedation, gait imbalance, and
cognitive impairment.
Ongoing, longitudinal, relatively large epidemiological studies
will improve our understanding of the evolution (e.g., cumulative
prevalence, incidence) and predictors of anxiety symptoms over
the course of PD. These studies either enroll de novo, untreated
PD patients at baseline (e.g., PPMI, DeNoPa, and ICICLE-PD) or
established PD patients (DEMPARK/LANDSCAPE), both of which
are informative. These studies typically include some multi-modal
neurobiological assessments, which will help improve our under-
standing of the neural substrate in PD.
In terms of treatment, there are ongoing RCTs of pharmacolo-
gical (e.g., rotigotine patch and buspirone) and non-
pharmacological (cognitive-behavioral therapy and mindfulness-
based stress reduction) treatments for anxiety in PD. There are also
clinical trials examining the treatment of non-motor symptoms,
including anxiety, broadly (e.g., levodopa-carbidopa intestinal gel
in advanced PD). Lacking are any RCTs examining the efficacy and
tolerability of commonly-used antidepressants or benzodiazepines
for anxiety in PD, and in the future, there will likely be studies
examining the effects of medical marijuana for this condition.
DISCUSSION
Of the many things that go wrong in PD, anxiety is certainly near
the top of the list of the neurobehavioral problems because of the
distress it causes and the prevalence. However, the number of
published studies has been impressively and embarrassingly
small. Until the 1980s, neurobehavioral studies focused on
depression, and, although depression and anxiety go hand in
hand, little attention was paid to anxiety. Anxiety in PD differs in a
few ways from that in the general population, affecting the
genders about equally, developing much later in life. A common
misconception is that it is a response to the disease or
embarrassment due to motor symptoms in social situations.
However, risk factors include young age at onset, more rapid
progression, more severe motor dysfunction, and motor fluctua-
tions—suggesting a biological link to PD. We don’t yet know the
natural history. Does it worsen, resolve or fluctuate over time?
Does it presage other neurobehavioral problems? One problem
has been the lack of validated scales, especially one validated in
patients with dementia. In the future remote monitoring of
anxiety in real time using at-home or mobile technology is likely to
provide a more reliable assessment of the phenomenology of
anxiety (including more objective signs such as heart rate
variability) and triggers that historical ‘out-of-anxious-state’
assessment cannot provide. To ensure the replication and
generalizability of conclusions from existing and future work on
anxiety in PD, standardized assessment and consistent methodol-
ogy are needed.
We have rudimentary data on neurotransmitter and physiolo-
gical changes associated with anxiety, based primarily on imaging
studies and animal observations. These implicate both dopamine
and serotonin, but how important this information will be to
developing an understanding and treatment remains unknown.
And, as a result of this weak data base, our drug therapies are
based almost entirely on observations in the general population.
Perhaps, almost incredibly, there have been no published trials
of medication treatment of anxiety. The only pharmacologic data
are based on the few antidepressant trials, where anxiety was a
secondary variable and the samples too small to infer results. Non-
pharmacologic therapies, e.g., CBT, have been proven helpful but
have not been widely embraced and access will remain logistically
difficult until we become more comfortable with telemedicine.
The participants universally endorsed a multidisciplinary approach
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to treating anxiety, including neurologists, psychiatrists and other
mental health care workers, as well as support personnel. Special
attention is needed for caregivers as well, since they are the front
line of support. Sometimes treating a caregiver may be more
important than treating the patient.
Future work needs to focus on all aspects of anxiety: defining
and validating measures in both demented and non-demented
patients; understanding its pathophysiology, probably through
imaging and possibly with biomarkers; monitoring its natural
history; developing drug treatments and improving non-drug
treatment. In the mean-while it is important to educate our
patients, their support systems and our colleagues, and try to
develop cost effective multidisciplinary models of care.
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